

Merus Labs International Inc.  
Form 6-K  
June 28, 2013

---

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION**  
Washington, D.C. 20549

**FORM 6-K**

**REPORT OF FOREIGN PRIVATE ISSUER**

**PURSUANT TO RULE 13a-16 OR 15d-16 OF  
THE SECURITIES EXCHANGE ACT OF 1934**

For the month of **June, 2013**

Commission File No. **00-30082**

**MERUS LABS INTERNATIONAL INC.**

(Translation of registrant's name into English)

**Suite 2007, 1177 West Hastings Street**

**Vancouver, BC V6E 2K3**

(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F  
**Form 20-F**  **Form 40-F**

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule  
101(b)(1)

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule  
101(b)(7)

---

**SUBMITTED HEREWITH**

| <b>Exhibits</b> |   |
|-----------------|---|
| <u>99.1</u>     | <u>News release dated June 3, 2013 announcing private placement</u>   |
| <u>99.2</u>     | <u>News release dated June 10, 2013 announcing the closing of the private placement</u>                         |
| <u>99.3</u>     | <u>Form 51-102F3 material change report dated June 17, 2013 announcing the closing of the private placement</u> |

---

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

Date: June 28, 2013

**MERUS LABS INTERNATIONAL INC.**

*/s/ Andrew Patient*

---

Andrew Patient  
Chief Financial Officer